Table 4.
Adverse events.
| ICI monotherapy
N = 40 |
ICI plus nab-paclitaxel
N = 17 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | Any | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | |
| Treatment related | ||||||||||
| Any | 28 (70.0%) | 27 (67.5%) | 1 (2.5%) | 0 | 0 | 12 (70.6%) | 8 (47.1%) | 3 (17.6%) | 1 (5.9%) | 0 |
| Nausea | 6 (15.0%) | 5 (12.5%) | 1 (2.5%) | 0 | 0 | 4 (23.5%) | 4 (23.5%) | 0 | 0 | 0 |
| Fatigue | 8 (20.0%) | 8 (20.0%) | 0 | 0 | 0 | 3 (17.6%) | 2 (11.8%) | 1 (5.9%) | 0 | 0 |
| Rash | 2 (5.0%) | 2 (5.0%) | 0 | 0 | 0 | 3 (17.6%) | 3 (17.6%) | 0 | 0 | 0 |
| Vomiting | 0 | 0 | 0 | 0 | 0 | 2 (11.8%) | 2 (11.8%) | 0 | 0 | 0 |
| Leukopenia | 4 (10.0%) | 4 (10.0%) | 0 | 0 | 0 | 2 (11.8%) | 2 (11.8%) | 0 | 0 | 0 |
| Neutropenia | 1 (2.5%) | 1 (2.5%) | 0 | 0 | 0 | 2 (11.8%) | 1 (5.9%) | 0 | 1 (5.9%) | 0 |
| Hypothyroidism | 0 | 0 | 0 | 0 | 0 | 1 (5.9%) | 1 (5.9%) | 0 | 0 | 0 |
| Increased alanine aminotransferase | 0 | 0 | 0 | 0 | 0 | 1 (5.9%) | 1 (5.9%) | 0 | 0 | 0 |
| Pneumonitis | 4 (10.0%) | 4 (10.0%) | 0 | 0 | 0 | 3 (17.6%) | 0 | 3 (17.6%) | 0 | 0 |
| Fever | 6 (15.0%) | 6 (15.0%) | 0 | 0 | 0 | 2 (11.8%) | 0 | 2 (11.8%) | 0 | 0 |
| Constipation | 1 (2.5%) | 1 (2.5%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Myalgia | 2 (5.0%) | 2 (5.0%) | 0 | 0 | 0 | 1 (5.9%) | 1 (5.9%) | 0 | 0 | 0 |
| Anemia | 4 (10.0%) | 4 (10.0%) | 0 | 0 | 0 | 2 (11.8%) | 2 (11.8%) | 0 | 0 | 0 |
| Appetite decreases | 2 (5.0%) | 2 (5.0%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 1 (2.5%) | 1 (2.5%) | 0 | 0 | 0 | 1 (5.9%) | 1 (5.9%) | 0 | 0 | 0 |